Core Viewpoint - Shineco, Inc. announces a stock purchase program led by CEO Jennifer Zhan and CFO Sam Wang, intending to buy up to $2,000,000 of the company's common stock, reflecting their belief that the stock is undervalued [1][3]. Company Overview - Shineco, Inc. focuses on providing innovative diagnostic medical products and related medical devices, aiming to improve quality of life through safe and efficient health products [3]. - The company has developed 33 types of in vitro diagnostic reagents and related medical devices, in addition to producing and selling healthy and nutritious foods [3]. Stock Purchase Program Details - The stock purchase program will involve open market purchases funded by the personal cash of Ms. Zhan and Mr. Wang, with a maximum purchase price of $1.50 per share [1][2]. - The timing and number of shares purchased will depend on various factors, including the company's business conditions and stock pricing [2]. Management's Perspective - CEO Jennifer Zhan emphasizes that the insider-led purchase initiative reflects management's confidence in Shineco's long-term growth potential and the belief that the current stock price does not accurately reflect the company's technological advantages and market potential [3].